Azitra Inc
Azitra, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing advanced therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. It has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its lead product, ATR-12, is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its advanced product, ATR-04, is a genetically modified strain of S. epidermidis for treating papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, a chronic, xerotic (abnormally dry), and scaly skin disease.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Azitra's stock with a target price of $105, indicating strong growth potential.
Financial Health
Azitra Inc has minimal revenue and cash flow, indicating significant financial challenges ahead.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring AZTR
Lottery Tickets
These visionary companies are betting it all on game-changing innovations that could revolutionize entire industries. Hand-selected by our analysts, each represents a high-risk, high-reward opportunity with potential for explosive growth if their breakthrough technologies succeed.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Skin Microbiome Focus
Azitra’s programmes target skin conditions using microbial and biologic approaches — an area of scientific interest, though clinical success is uncertain.
Early-stage Outcomes
Clinical data and regulatory updates can drive sharp moves in the share price; investors should expect high event-driven volatility.
Micro-cap Considerations
With a market cap around $2.05M, liquidity and financing are meaningful risks; suitable only for those comfortable with high-risk investments.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
